CN119053335A - 包含酸中和聚合物用于口服活性剂的制剂 - Google Patents
包含酸中和聚合物用于口服活性剂的制剂 Download PDFInfo
- Publication number
- CN119053335A CN119053335A CN202380034392.0A CN202380034392A CN119053335A CN 119053335 A CN119053335 A CN 119053335A CN 202380034392 A CN202380034392 A CN 202380034392A CN 119053335 A CN119053335 A CN 119053335A
- Authority
- CN
- China
- Prior art keywords
- composition
- receptor
- therapeutically active
- polymer
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263313363P | 2022-02-24 | 2022-02-24 | |
| US63/313,363 | 2022-02-24 | ||
| PCT/IL2023/050192 WO2023161934A1 (en) | 2022-02-24 | 2023-02-23 | Formulations comprising acid-neutralizing polymer for oral administration of active agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119053335A true CN119053335A (zh) | 2024-11-29 |
Family
ID=87765060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380034392.0A Pending CN119053335A (zh) | 2022-02-24 | 2023-02-23 | 包含酸中和聚合物用于口服活性剂的制剂 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250186558A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4482507A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025506821A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240152915A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119053335A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023226618A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3251862A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315198A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024010387A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023161934A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025046589A1 (en) * | 2023-08-30 | 2025-03-06 | Entera Bio Ltd. | Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5175553B2 (ja) * | 2005-02-01 | 2013-04-03 | エミスフェアー・テクノロジーズ・インク | 胃内滞留および制御放出型送達系 |
| WO2008070543A1 (en) * | 2006-12-01 | 2008-06-12 | Emisphere Technologies Inc. | Improved acyclovir formulations |
| US20090124639A1 (en) * | 2007-11-06 | 2009-05-14 | Emisphere Technologies Inc. | valacyclovir formulations |
| WO2016128972A1 (en) * | 2015-02-09 | 2016-08-18 | Entera Bio Ltd. | Formulations for oral administration of active agents with controlled absorption profile |
| MX2019001850A (es) * | 2016-08-17 | 2019-05-15 | Entera Bio Ltd | Formulaciones para administracion oral de principios activos. |
| WO2018121702A1 (zh) * | 2016-12-30 | 2018-07-05 | 江苏恒瑞医药股份有限公司 | 一种glp-1类似物的药物组合物及其制备方法 |
| CN112587496A (zh) * | 2020-12-16 | 2021-04-02 | 江苏海洋大学 | 一种艾塞那肽肠溶胶囊及其制备方法 |
-
2023
- 2023-02-23 KR KR1020247031757A patent/KR20240152915A/ko active Pending
- 2023-02-23 EP EP23759464.3A patent/EP4482507A4/en active Pending
- 2023-02-23 JP JP2024550241A patent/JP2025506821A/ja active Pending
- 2023-02-23 CA CA3251862A patent/CA3251862A1/en active Pending
- 2023-02-23 IL IL315198A patent/IL315198A/en unknown
- 2023-02-23 AU AU2023226618A patent/AU2023226618A1/en active Pending
- 2023-02-23 US US18/841,377 patent/US20250186558A1/en active Pending
- 2023-02-23 CN CN202380034392.0A patent/CN119053335A/zh active Pending
- 2023-02-23 MX MX2024010387A patent/MX2024010387A/es unknown
- 2023-02-23 WO PCT/IL2023/050192 patent/WO2023161934A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025506821A (ja) | 2025-03-13 |
| WO2023161934A1 (en) | 2023-08-31 |
| MX2024010387A (es) | 2024-09-04 |
| EP4482507A1 (en) | 2025-01-01 |
| IL315198A (en) | 2024-10-01 |
| US20250186558A1 (en) | 2025-06-12 |
| EP4482507A4 (en) | 2026-02-18 |
| CA3251862A1 (en) | 2023-08-31 |
| AU2023226618A1 (en) | 2024-10-03 |
| KR20240152915A (ko) | 2024-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7736834B2 (ja) | 活性薬剤の経口投与のための製剤 | |
| US20260124281A1 (en) | Formulations comprising acid-neutralizing polymer for oral administration of parathyroid hormone | |
| CN119031930A (zh) | 包含酸中和聚合物用于口服胰高血糖素样肽-1及其类似物的制剂 | |
| WO2023161938A1 (en) | Formulations comprising acid-neutralizing polymer for oral administration of kappa opioid receptor agonist peptide | |
| JP2025506821A (ja) | 活性薬剤の経口投与用の酸中和ポリマーを含む製剤 | |
| KR20260061220A (ko) | 활성 제제의 경구 투여를 위한 산 중화 중합체성 및 비중합체성 물질의 조합을 포함하는 제형 | |
| CN119031929A (zh) | 包含酸中和聚合物用于口服胰高血糖素样肽-2的制剂 | |
| WO2025046590A1 (en) | Formulations for oral administration of active agents | |
| WO2023161935A1 (en) | Formulations comprising acid-neutralizing polymer for oral administration of growth hormone | |
| WO2023161936A1 (en) | Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone | |
| HK40101653A (en) | Formulations for oral administration of active agents | |
| HK40101429A (en) | Formulations for oral administration of active agents | |
| BR122024010024A2 (pt) | Forma de dosagem multiunitária de composição farmacêutica, uso de uma forma de dosagem multiunitária de composição farmacêutica, uso de uma forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária, e, kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |